AlzChem Group (XTRA:ACT) Stock Price Slides As EPS Strength Defies Selloff

AlzChem Group stock has slipped over the past week and month, yet the latest earnings print tells a more resilient story than the recent price chart suggests. At around €153.9 a share, investors are reacting to shorter term noise while the chemistry specialist continues to put up solid profit per share and healthy net income.

The headline this quarter is earnings power. Basic earnings per share for recent quarters sit comfortably above €1.70 and trailing net margins stand in the low double digits. For anyone thinking beyond the next few trading days, the gap between profit trends and share price performance is hard to ignore.

If you like AlzChem Group's earnings strength but want more ideas where consistent profits align more closely with recent share price action, take a look at our curated list of list of solid balance sheet and fundamentals stocks (412 results).

Q2 2026 Earnings Summary

• Revenue (Q1 2026 vs. Q1 2025): €155.992 million vs. €149.943 million (up about 4%)
• Net Income (Excl. Extra Items, Q1 2026 vs. Q1 2025): €17.958 million vs. €14.593 million (up about 23%)
• Basic EPS (Earnings Per Share, Q1 2026 vs. Q1 2025): €1.77 vs. €1.44 (up about 23%)
• Net Profit Margin (Trailing Twelve Months, latest vs. prior year): 11.5% vs. 10.1% (improved by about 1.4 percentage points)

Prefer clear charts instead of scrolling through another wall of earnings tables and raw figures? View AlzChem Group's full financial picture, including its earnings and profitability trends, in our company report for AlzChem Group.

AlzChem Group’s Earnings Story Versus Bull Hopes

The bullish story around AlzChem Group rests on three things: capacity-led growth in higher value specialties, margin lift from process efficiency, and early proof that the U.S. expansion is moving from concept to execution. The Q1 2026 numbers give partial support.

Revenue of €155.992 million and basic EPS of €1.77, together with a trailing margin of 11.5%, indicate that earnings power is holding up and margin quality is improving. That aligns with claims of better process efficiency and mix, even as the share price has fallen about 13% over 7 days and about 10% over 30 days.

On the U.S. side, the Bushy Park site decision is a clear milestone hit. It confirms the nitroguanidine project is progressing toward physical build-out. However, construction is only planned from 2027, so none of the expected U.S. revenue or margin benefits are visible yet.

Compare AlzChem Group’s improving margins and profit per share with what institutions are pricing in. Reveal the consensus price target analysis for AlzChem Group

AlzChem Group Bears Still Waiting For Real Stress

The clearest bearish claim is that AlzChem Group faces structurally squeezed margins from high German energy costs and tough competition, especially from China, which could cap earnings and make new projects fragile. Q1 2026 numbers do not show that squeeze yet. Revenue is €155.992 million and net margin on a trailing basis is 11.5%, which is higher than the prior 10.1%. Basic EPS of €1.77 also sits comfortably ahead of last year.

Where bears still have room is on execution and concentration risk. The Bushy Park decision is a site choice, not yet a cash generating asset. Construction is planned from 2027, so there is no evidence yet that U.S. expansion can offset any future pressure on German production. Product mix remains heavily tied to a few core lines, and this update gives no fresh data that materially diversifies that exposure.

With multi year earnings growth and a premium P/E already in place, the real question is whether AlzChem Group has the balance sheet and cash generation to support its expansion plans. Check the financial health analysis of AlzChem Group stock.

Stay Ahead Of Your Next Move

If AlzChem Group's solid recent EPS and margins have caught your eye but the recent share price pullback gives you pause, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and wait for a setup that fits your plan. Once you own shares, keep your focus on what matters by using the Portfolio Command Center to cut through market noise and surface only the most important updates on your holdings. Over time, compare your thinking with other investors and spot fresh angles through the Community. By surfacing potential catalysts and risks early, you can act with more confidence and stay ahead of the market.

Seeking Alternatives Beyond AlzChem Group?

Fresh stock ideas can break out fast and leave latecomers chasing momentum. Scan curated lists while they are still under the radar for now and get in early.

• Spot potential breakout yield opportunities by running through a curated set of income plays in the 430 dividend fortresses before prices move away from current levels.
• Ride the next wave of AI momentum by reviewing hand picked companies in the 57 AI infrastructure stocks while they remain under followed and pricing still reflects early expectations.
• Catch potential upside in hard assets by checking a focused group of producers via the 8 top copper producer stocks before any renewed interest starts driving valuations higher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com